|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Merck |
|---|---|
| Information provided by: | Merck |
| ClinicalTrials.gov Identifier: | NCT00092742 |
Purpose
The purpose of this study is to evaluate the long-term safety of an investigational drug versus an approved drug for the relief of pain in patients with rheumatoid arthritis.
| Condition | Intervention | Phase |
|---|---|---|
|
Rheumatoid Arthritis |
Drug: MK0663, etoricoxib Drug: Comparator: Diclofenac sodium |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety Study |
| Official Title: | A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis |
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | Merck Sharp & Dohme Corp ( Executive Vice President, Clinical and Quantitative Sciences ) |
| Study ID Numbers: | 2004_055, MK0663-072 |
| Study First Received: | September 23, 2004 |
| Last Updated: | January 21, 2010 |
| ClinicalTrials.gov Identifier: | NCT00092742 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Arcoxia |
|
Anti-Inflammatory Agents Autoimmune Diseases Molecular Mechanisms of Pharmacological Action Immune System Diseases Joint Diseases Cyclooxygenase Inhibitors Physiological Effects of Drugs Etoricoxib Arthritis, Rheumatoid Diclofenac Enzyme Inhibitors Rheumatic Diseases |
Pharmacologic Actions Musculoskeletal Diseases Sensory System Agents Analgesics, Non-Narcotic Therapeutic Uses Arthritis Connective Tissue Diseases Anti-Inflammatory Agents, Non-Steroidal Peripheral Nervous System Agents Analgesics Antirheumatic Agents Central Nervous System Agents |